Document Reuse: Theory and Practice

Size: px
Start display at page:

Download "Document Reuse: Theory and Practice"

Transcription

1 Document Reuse: Theory and Practice Peggy Boe, RN Sr. Director, Medical Writing Image Solutions, Inc (ISI) Company logo here

2 Best Practice: Single Sourcing Creating reusable text and information Requires careful consideration of which documents contain similar/same text or data Submitting as IND in ectd format maximizes this best practice efficiency

3 21 CFR Item 5: IB CMC Nonclinical Clinical

4 ICH E6 GCP: Section 7 Purpose: To document that relevant and current scientific information about the investigational product has been provided to the investigator 1. Summary 2. Introduction 3. Physical, chemical, and pharmaceutical properties and formulation 4. Nonclinical studies 4.1 Nonclinical pharmacology 4.2 Pharmacokinetics and product metabolism in animals 5. Effects in humans 5.1 Pharmacokinetics and product metabolism in humans 5.2 Safety and efficacy 5.3 Marketing experience 6. Summary of data and guidance for the investigator This outline includes the minimum information that should be included (ICH E6: 7.1).

5 Who Reads the IB? Investigators and other study participants p (ICH E6: 4.1.2, 5.6.2) IRBs (ICH E6: 3.1.2, 4.4.2) Food and Drug Administration (FDA) Medical Writers

6 IB Content Presentation Concise Simple Objective Balanced Non-promotional GOAL: Enable a clinician or potential investigator, IRB, and FDA to understand it and make unbiased risk-benefit assessment of the appropriateness of the proposed trial

7 What Are the Source Documents? 1. Drug / Clinical Development Plan (DDP or CDP) 2. Target Product Profile (TPP) 3. Literature search 4. Chemistry, Manufacturing, and Control (CMC) documents 5. Nonclinical Study Reports 6. Protocols 7. Clinical Study Reports

8 beginning with the goal in mind TPP template developed by FDA-PhRMA working group Target (Language that the sponsor hopes to achieve) Annotations (Summary information regarding completed or planned studies) Comments (To provide clarity) Links each specific labeling concept to a specific study or other source of data Source: Jeanne M. Delasko, FDA. DIA Annual Conference, FDA Labeling Update. 28 June 2005

9 Template Example

10 Appendix C: Template

11 TPP Format Labeling Format* 1. Indications and Usage 2. Dosage and Administration 3. Dosage Forms and Strengths 4. Contraindications 5. Warnings and Precautions 6. Adverse Reactions 7. Drug Interactions Highlights of Prescribing Information Full Prescribing Information: Contents Full Prescribing Information 1. Indications and Usage 2. Dosage and Administration 3. Dosage Forms and Strengths 4. Contraindications 5. Warnings and Precautions 6. Adverse Reactions 7. Drug Interactions 8. Use in Specific Populations 8. Use in Specific Populations 9. Drug Abuse and Dependence 9. Drug Abuse and Dependence 10. Overdosage 10. Overdosage 11. Description 11. Description 12. Clinical Pharmacology 12. Clinical Pharmacology 13. Nonclinical Toxicology 13. Nonclinical Toxicology 14. Clinical Studies 14. Clinical Studies 15. References 15. References 16. How Supplied/Storage and Handling 17. Patient Counseling Information 16. How Supplied/Storage and Handling 17. Patient Counseling Information *Draft guidance January 2006

12 Traditional IND or ectd IND? CTD Guidance: US Module 1 Regional Information Source: FDA ectd Comprehensive Table of Contents Headings and Hierarchy,

13 Target Product Profile 3. Dosage Forms and Strengths 11. Description 16. How Supplied/Storage and Handling Investigator s s Brochure Table of Contents List of Abbreviations 1. Summary 2. Introduction 3. Physical, chemical, and pharmaceutical properties and formulation H dli 4. Nonclinical studies 6. Adverse Reactions 7. Drug Interactions 8. Use in Specific Populations 9. Drug Abuse and Dependence 10. Overdosage 12. Clinical Pharmacology 14. Clinical Studies 4.1 Nonclinical pharmacology 4.2 Pharmacokinetics and product metabolism in animals 4.3 Toxicology 5. Effects in humans 51Ph 5.1 Pharmacokinetics and product metabolism in humans 5.2 Safety and efficacy 5.3 Marketing experience 6. Summary of data and guidance for the investigator

14 Nonclinical Text & Data Organization Order study summaries as they appear in the Module 2.6 Written Summaries and Module 4 Species Route Duration Reuse the 2.6 Tabulated Summaries in the IB

15 Target Product Profile Investigator s s Brochure 1. Indications and Usage Table of Contents List of Abbreviations 2. Dosage and Administration 1. Summary 3. Dosage Forms and Strengths 2. Introduction 4. Contraindications 3. Physical, chemical, and 5. Warnings and Precautions pharmaceutical properties and formulation 6. Adverse Reactions 4. Nonclinical studies 7. Drug Interactions 4.1 Nonclinical 8. Use in Specific Populations pharmacology 9. Drug Abuse and Dependence 4.2 Pharmacokinetics and 10. Overdosage product metabolism in animals 11. Description 4.3 Toxicology 12. Clinical Pharmacology 5. Effects in humans 13. Nonclinical Toxicology 51Ph 5.1 Pharmacokinetics and 14. Clinical Studies product metabolism in humans 15. References 5.2 Safety and efficacy 16. How Supplied/Storage and Handling 5.3 Marketing experience 17. Patient Counseling Information 6. Summary of data and guidance for the investigator

16 IB Updates Typical scenario Add all new material Do it as fast as you can Consider a redact

17 Step #1: Revise Existing Content Restructure nonclinical if it doesn t mimic 2.6 Delete irrelevant data (fun!) Check source docs for accuracy and thoroughness in IB Check IB text for additional data to be included in tables Delete text redundant with tables Rewrite/summarize key messages from data interpretation

18 Step #2: Add New Content Acquire newly released study reports or updated summaries Determine appropriate location (subset reports) Populate the tables with new data Make sure any new authors understand the goals for structuring with the CTD in mind Keep any new text to a concise minimum

19 Investigator s Brochure Labeling Format 1. Summary 1. Indications and Usage 2. Introduction 2. Dosage and Administration 3. Physical, chemical, and 3. Dosage Forms and Strengths pharmaceutical properties 4. Contraindications and formulation 5. Warnings and Precautions 5. Effects in humans 7. Drug Interactions 6. Summary of data and 8. Use in Specific Populations guidance for the investigator 9. Drug Abuse and Dependence 10. Overdosage 11. Description 12. Clinical Pharmacology 13. Nonclinical Toxicology 14. Clinical Studies 15. References 16. How Supplied/Storage and Handling 17. Patient Counseling Information

20 IND Case Study: Lessons Learned Compiling the IND should not be a lastminute effort Nonclinical study reports should be organized and data captured in a reusable format ongoing process Writing sequence is key to best efficiency 1. Literature search 2. Nonclinical summaries 3. IB 4. Protocol Establish review processes, stylistic issues, templates, version control very early

21 Marketing Applications Lessons Learned Plan for your marketing application from the start of your product development program Develop strategic relationships with professional writers who can help keep your growing library of documents consistent, t organized Use tools available to you to maintain i (or adjust) the key messages from IND all the way to the marketing label

22 Conclusions Drug development should begin with the end in mind Medical Writers should be involved in most regulatory documents Single-sourcing text/data is necessary for best efficiencies i i The ectd IND maximizes that efficiency Start early if you want to change over from paper to ectd At the very least, do begin now creating your submission i using CTD structure

23 Questions?

OASIS DITA Pharma. Initial Meeting 30 July 2009

OASIS DITA Pharma. Initial Meeting 30 July 2009 OASIS DITA Pharma Initial Meeting 30 July 2009 Agenda DITA PCSC Welcome Objectives of today s meeting Introductions Round Robin Expectations of the Group Round Robin Story Boards of Opportunity DITA in

More information

The Investigator s Brochure: A multidisciplinary document

The Investigator s Brochure: A multidisciplinary document The Investigator s Brochure: A multidisciplinary document Douglas Fiebig Trilogy Writing & Consulting GmbH, Frankfurt am Main, Germany Correspondence to: Douglas Fiebig Trilogy Writing & Consulting GmbH,

More information

Quality by design and reproducible aspects. of a study on targetable polyacrylamide and ultrasound contrast agents

Quality by design and reproducible aspects. of a study on targetable polyacrylamide and ultrasound contrast agents Quality by design and reproducible aspects of a study on targetable polyacrylamide and ultrasound contrast agents 1 2 From Molecule to Market Agenda QbD in Design, Analysis and Generalization of Statistically

More information

THE COMMON TECHNICAL DOCUMENT: TAKING INDIAN NDA PROCESS TOWARDS GLOBALIZATION

THE COMMON TECHNICAL DOCUMENT: TAKING INDIAN NDA PROCESS TOWARDS GLOBALIZATION Review Article Bhalodiya H. A.*, Boda J. M., Shah J. S., Patel P. B., Vaghela J. P. Department of Quality Assurance, S. J. Thakkar Pharmacy College, Rajkot-360005, Gujarat, India. *Corresponding author

More information

Innovative Clinical Development Solutions

Innovative Clinical Development Solutions Innovative Clinical Development Solutions From Protocol to Package Insert: A Data Journey AMWA Medical Writing & Communication Conference Thursday, November 1, 2018 Introductions Alex Rohall Senior Manager,

More information

Structured Product Labeling Project for the DailyMed Initiative. June 4, 2004

Structured Product Labeling Project for the DailyMed Initiative. June 4, 2004 Structured Product Labeling Project for the DailyMed Initiative June 4, 2004 1 Purpose Improve patient safety through accessible product information Support initiatives to improve patient care by better

More information

Investigational New Drug Application

Investigational New Drug Application Investigational New Drug Application Regulatory Sponsor: Funding Sponsor: Study Product: Protocol Number: Name of the Sponsor-Investigator Department Name Address Phone Number Name of Primary Funding Institution

More information

Vaccine Prequalification Dossier

Vaccine Prequalification Dossier Vaccine Prequalification Dossier Introduction The current process for prequalification of vaccines states that once a product is eligible for prequalification evaluation the manufacturer must submit a

More information

Development Safety Update Report Guidance

Development Safety Update Report Guidance Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational

More information

Creating, Managing and Delivering Regulated Content in Pharma. Jim Nichols VP, US Operations & Life Sciences DitaExchange Inc.

Creating, Managing and Delivering Regulated Content in Pharma. Jim Nichols VP, US Operations & Life Sciences DitaExchange Inc. Creating, Managing and Delivering Regulated Content in Pharma Jim Nichols VP, US Operations & Life Sciences DitaExchange Inc. DitaExchange simplifies the way organizations Create Manage Deliver Re-use

More information

Labelling Harmonization 2011

Labelling Harmonization 2011 Labelling Harmonization 2011 DIA, Bethesda, MD Core Labeling During Clinical Development Su Yueh Lin Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual

More information

How to put together an IND application

How to put together an IND application How to put together an IND application Judit Milstein, Chief, Project Management Staff Judit.milstein@fda.hhs.gov Eithu Lwin, Regulatory Health Project Manager Eithu.Lwin@fda.hhs.gov Division of Transplant

More information

OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE

OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE 1. Purpose: To describe the procedures related to the development of protocol and investigational

More information

Standard Operating Procedure (SOP) Research and Development Office

Standard Operating Procedure (SOP) Research and Development Office Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Creation & Maintenance of an Investigator Brochure SOP Number: 34 Version Number: 1.0 Supercedes: N/A Effective date: August

More information

Re: Docket No. FDA-2008-D-0386: International Conference on Harmonisation; Draft Guidance on E2F Development Safety Update Report; Availability.

Re: Docket No. FDA-2008-D-0386: International Conference on Harmonisation; Draft Guidance on E2F Development Safety Update Report; Availability. 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org November 03, 2008 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,

More information

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November 2010 1 Objectives Identify the importance of accuracy,

More information

Ensuring Quality of Regulatory Clinical Documents

Ensuring Quality of Regulatory Clinical Documents Ensuring Quality of Regulatory Clinical Documents Henry Li *, Kim Hanna and Steve Petteway Talecris Biotherapeutics, Research Triangle Park, North Carolina, USA Summary A large number of clinical documents

More information

Author Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document

Author Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document SOP Title: Investigator s Brochure Content, Design, Amendments, Filing & Distribution Author: Clinical Research and Development Office (CRDO) Author Signature: Date: 10 October 2017 The author is signing

More information

DIA Document & Records Management SIAC

DIA Document & Records Management SIAC DIA Document & Records Management SIAC EDM Reference Model Clinical Domain John Aitken, PhD Director, Regulatory Operations Gilead Sciences Inc Points to Cover Clinical Domain In scope: CTD clinical documents

More information

Guidance for Industry

Guidance for Industry Guidance for Industry M4S: The CTD Safety U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research

More information

IND Development Process Published on ResearchGo UCLA (

IND Development Process Published on ResearchGo UCLA ( IND Development Process IND Development Overview The Pre-IND Process The IND Study Protocol Preparing the Initial IND Submission Filing the IND Maintaining the IND IND Templates, Education and Useful Links

More information

September 12, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

September 12, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 September 12, 2013 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: : Draft Guidance for Industry on Pediatric Study Plans: Content

More information

Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development

Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality

More information

Investigational New Drug Development Steps for CRCs

Investigational New Drug Development Steps for CRCs Investigational New Drug Development Steps for CRCs Natalie Nardone, PhD Program Manager, Department of Medicine CRC Instructor, Office of Clinical Research Contact: natalie.nardone@ucsf.edu Learning Objectives

More information

Non-clinical documentation Overview of Requirements

Non-clinical documentation Overview of Requirements 3 rd EMEA-. Non-clinical Aspects Non-clinical documentation Overview of Requirements EMEA Pre-Authorisation Human Unit 3 rd EMEA-. Non-clinical Aspects Outline Overview of Legal and Regulatory requirements

More information

Re: Docket No. FDA-2015-D-1246: Draft Guidance on Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment

Re: Docket No. FDA-2015-D-1246: Draft Guidance on Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment July 13, 2015 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2015-D-1246: Draft Guidance on Investigational Enzyme Replacement

More information

Sponsor-Investigator Responsibilities In Clinical Trials

Sponsor-Investigator Responsibilities In Clinical Trials In Clinical Trials Margaret Huber, RN, BSN, CHRC Compliance Manager The lecturer has no conflicts for this presentation 9/23/2015 Objectives Define terms sponsor, investigator, and sponsor-investigator.

More information

Introduction to CMC Regulatory Affairs

Introduction to CMC Regulatory Affairs Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4

More information

Clinical trial applications in the EU and US

Clinical trial applications in the EU and US Clinical trial applications in the EU and US Alain Patat, M.D. Translational Development Wyeth Research Paris, France AGAH-Club Phase 1 1 st Symposium Strasbourg 17-18 March 2005 Overview of the presentation

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS

More information

Role of Academic Investigators in Drug Development

Role of Academic Investigators in Drug Development DTRCS Regulatory Education Seminar, June 12, 2007 Role of Academic Investigators in Drug Development Howard Lee, MD, PhD Associate Adjunct Professor Director, Center for Drug Terminology Sponsor Investigator

More information

Chin Koerner Executive Director US Regulatory and Development Policy

Chin Koerner Executive Director US Regulatory and Development Policy Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com

More information

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS As a full service contract research organisation performing phase I to IV clinical trials across Europe and the Americas for 40

More information

ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3

ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3 European Medicines Agency June 2009 EMEA/CHMP/ICH/380636/2009 ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions Step 3 NOTE FOR GUIDANCE

More information

Question and Answer Guide Regarding Notification on Practical Operations of Electronic Study Data Submissions

Question and Answer Guide Regarding Notification on Practical Operations of Electronic Study Data Submissions Administrative Notice April 27, 2015 To: Prefectrual Health Department (Bureau) Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Question

More information

CMC Strategy Forum Japan November Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration

CMC Strategy Forum Japan November Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration CMC Strategy Forum Japan 2015 9-10 November 2015 Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration 1 1. Background 2. Organization Chart 3. Biological Products 4. Regulation

More information

Standard Operating Procedures (SOPs)

Standard Operating Procedures (SOPs) Organizational Strategies for Clinical Trials Standard Operating Procedures (SOPs) SUSAN JACKSON, MPA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE UNC CENTER

More information

Dossier for marketing authorization in the European Union

Dossier for marketing authorization in the European Union Dossier for marketing in the European Union Maida Todi} Institute of Pharmacology, Clinical Pharmacology and Toxicology "Pavel Stern", Faculty of Medicine, University of Sarajevo, Abstract Extensive and

More information

ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA

ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA Disclaimer The views and opinions expressed in the following PowerPoint slides are those

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Submission of Abbreviated Reports and Synopses in Support of Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Medicines for Children

Medicines for Children ICT Regulatory: Paediatrics Medicines for Children When preparing a paediatric investigation plan application, an experienced medical writer should be on hand to help interpret the requirements of the

More information

How to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER

How to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco

More information

IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES

IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES Karen Weaver Epstein, Becker & Green Health Care & Life Sciences Practice APPLICABLE REGULATIONS 21 CFR 312

More information

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA

More information

Expanded Access and the Individual Patient IND

Expanded Access and the Individual Patient IND Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office

More information

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015 Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route

More information

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,

More information

Acceptance of Foreign Clinical Data A U.S. Perspective

Acceptance of Foreign Clinical Data A U.S. Perspective Acceptance of Foreign Clinical Data A U.S. Perspective Robert L. Justice, M.D., M.S. 9 th Kitasato University Harvard School of Public Health Symposium Disclaimer The views expressed in this presentation

More information

Office for Human Subject Protection. University of Rochester

Office for Human Subject Protection. University of Rochester POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,

More information

QbD (Quality by Design) Has industry benefited from this? WHITE PAPER.

QbD (Quality by Design) Has industry benefited from this? WHITE PAPER. WHITE PAPER www.makrocare.com/consulting There are many facets to engineering for a healthier world. It is important to understand what surrounds us today and look into what we believe will surround us

More information

Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry

Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Common CSR Template Mapped to ICH E3 and CORE Guidance

Common CSR Template Mapped to ICH E3 and CORE Guidance Common CSR Template Mapped to ICH E3 and CORE Guidance ICH E3 CORE Common CSR Rationale 1. TITLE PAGE 1. TITLE PAGE TITLE PAGE Per CORE, title page does not 2. SYNOPSIS 2. SYNOPSIS SYNOPSIS require a Heading

More information

Attachment B: A Guideline for Writing a Clinical Protocol for CPRN

Attachment B: A Guideline for Writing a Clinical Protocol for CPRN Attachment B: A Guideline for Writing a Clinical Protocol for CPRN This document provides guidelines for protocol submission. It is only guidance, and the format in which you choose to present the information

More information

FDA > CDRH > CFR Title 21 Database Search

FDA > CDRH > CFR Title 21 Database Search Seite 1 von 7 FDA Home Page CDRH Home Page Search A-Z Index 510 (k) Registration Listing Adverse Events PMA Classification CLIA CFR Title 21 Advisory Committees Assembler Recalls Guidance Standards New

More information

Investigational New Drug Applications: two cases

Investigational New Drug Applications: two cases Investigational New Drug Applications: two cases April 15, 2009 Carine M. Lenders, M.D., M.S. Medical Director, NFL program Director, Pediatric Nutrition Support Services Research Staff, General Pediatrics

More information

Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices

Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Jason Jobson, BLS, CCRP Research Compliance Officer Oklahoma City VA Medical Center October 2017 Goals Investigational New Drug

More information

Conducted Under an IND to Support a

Conducted Under an IND to Support a Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.

More information

Chapter 2 The Regulatory Environment

Chapter 2 The Regulatory Environment Chapter 2 The Regulatory Environment The relevance and importance of the regulatory environment cannot be overemphasized. 2.1 Introduction This chapter introduces the regulatory environment in which new

More information

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of Intermediate-size Patient Populations with an Investigational Drug or a REMS-restricted, Approved

More information

Disclaimer. Introduction 2/1/2016. The views expressed in this talk represent my opinions and do not necessarily represent the views of the FDA.

Disclaimer. Introduction 2/1/2016. The views expressed in this talk represent my opinions and do not necessarily represent the views of the FDA. Christopher D. Breder, MD PhD Division of Neurology Products Food and Drug Administration Disclaimer The views expressed in this talk represent my opinions and do not necessarily represent the views of

More information

To document the review procedures for a submission regarding compassionate/treatment use of investigational drugs, biologics and devices.

To document the review procedures for a submission regarding compassionate/treatment use of investigational drugs, biologics and devices. UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD COMPASSIONATE/TREATMENT USE OF MEDICAL DRUGS, BIOLOGICS AND DEVICES I. PURPOSE To document the review procedures for a submission

More information

Global Clinical Trials in Korea

Global Clinical Trials in Korea Global Clinical Trials in Korea In-Sook Park Department of Drug Evaluation Korea Food & Drug Administration Contents Regulatory changes relevant to Clinical Trials in Korea Current Status of Clinical Trials

More information

Agency Information Collection Activities; Submission for Office of Management and Budget

Agency Information Collection Activities; Submission for Office of Management and Budget This document is scheduled to be published in the Federal Register on 02/12/2019 and available online at https://federalregister.gov/d/2019-01962, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND

More information

Cardinal Health Specialty Solutions. Bringing a new drug to life. Regulatory Sciences

Cardinal Health Specialty Solutions. Bringing a new drug to life. Regulatory Sciences Cardinal Health Specialty Solutions Bringing a new drug to life Regulatory Sciences How we guided a pharma s breakthrough vision to commercial reality The right drug can mean the difference between life

More information

Quality Assurance in Clinical Trials

Quality Assurance in Clinical Trials Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:

More information

SPECIAL EDITION. the backbone of clinical development

SPECIAL EDITION. the backbone of clinical development SPECIAL EDITION Medical writing the backbone of clinical development 2017 Medical Writing: The Backbone of Clinical Development Medical Writing for Submission to Asia-Pacific Regulatory Authorities The

More information

RUTGERS IJOBS WORKSHOP REGULATORY WRITING JANUARY 30, 2018

RUTGERS IJOBS WORKSHOP REGULATORY WRITING JANUARY 30, 2018 1 RUTGERS IJOBS WORKSHOP REGULATORY WRITING JANUARY 30, 2018 Doreen W Lechner, PhD Program Director, MS Clinical Trial Sciences Program Biopharma Educational Initiative Rutgers School of Health Professions

More information

The Right Prescription for Working with Investigational Drug Service at BMC

The Right Prescription for Working with Investigational Drug Service at BMC The Right Prescription for Working with Investigational Drug Service at BMC Andrew Schoch Pharmacy Intern Northeastern University Class of 2010 Hyeseon Hong, Pharm.D. IDS Pharmacy Manager What is Investigational

More information

This template is to be used by companies willing to submit an overview of relevant

This template is to be used by companies willing to submit an overview of relevant Briefing book template for pharmaceuticals to support a multi-hta Early Dialogue (ED) December 13 th, 2013 This template is to be used by companies willing to submit an overview of relevant information

More information

Session 7 Clinical Trial Assessment Bioequivalence Studies

Session 7 Clinical Trial Assessment Bioequivalence Studies L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office

More information

Preclinical Data Standardization Process for regulatory submission to U.S. Food and Drug Administration

Preclinical Data Standardization Process for regulatory submission to U.S. Food and Drug Administration Preclinical Data Standardization Process for regulatory submission to U.S. Food and Drug Administration Gabriele Pesavento, 23 May 2018 Aptuit An Evotec company A full service CRO that delivers purpose

More information

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949 ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are

More information

REGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts

REGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts REGULATORY ISSUES: HOW TO APPLY FOR AN IND Penny Jester and Maaike Everts Outline 2 What is the purpose of an IND? What types of INDs are there? When do you need one? How do you apply for one? How do you

More information

Question-based Review (QbR)

Question-based Review (QbR) Question-based Review (QbR) Rebecca L. Owen, Ph.D. Team Leader, Feed/Topical Team Division of Manufacturing Technologies ONADE/CVM/FDA Outline Background on CMC Filing Requirements What is QbR? QbR at

More information

Guidelines for Setting Up a Regulatory Binder

Guidelines for Setting Up a Regulatory Binder Guidelines for Setting Up a Regulatory Binder Prepare for an audit Georgamaly Estronza, MS UPR - Medical Sciences Campus IRB Administrator - Compliance Officer Email: georgamaly.estronza@upr.edu Introduction

More information

Compassionate Use Navigator Information for Physicians

Compassionate Use Navigator Information for Physicians Compassionate Use Navigator Information for Physicians Contact: Elena Gerasimov, Program Director, Elena@kidsvcancer.org. As a physician, you must have wished there would be more treatment options for

More information

International Consortium For Innovation & Quality in Pharmaceutical Development

International Consortium For Innovation & Quality in Pharmaceutical Development International Consortium For Innovation & Quality in Pharmaceutical Development s on Draft Guidance: FDA Draft Guidance: Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment (draft

More information

The Role of the Writer in Regulatory Affairs. Julie Bowdler 19 May 2014

The Role of the Writer in Regulatory Affairs. Julie Bowdler 19 May 2014 The Role of the Writer in Regulatory Affairs Julie Bowdler 19 May 2014 How I became a regulatory writer Degree in Biochemistry DPhil in Neuropharmacology Medical publishing and conference organization

More information

ICH Q12 Perspectives: The Robust PQS

ICH Q12 Perspectives: The Robust PQS ICH Q12 Perspectives: The Robust PQS PQRI October 5 th, 2015 Mahesh Ramanadham, Pharm.D./MBA Branch Chief, Inspection Assessment Branch 2 Division of Inspection Assessment Office of Process and Facilities

More information

Introduction to Clinical Research

Introduction to Clinical Research Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that

More information

Comments and suggestions from reviewer

Comments and suggestions from reviewer Comments and suggestions from reviewer Page 1 of 13 Title: WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology: WHO/rDNA_DRAFT/12

More information

Appendix 3: Another look at the US IND annual report

Appendix 3: Another look at the US IND annual report Appendix 3: Another look at the US IND annual report As the Development Safety Update Report (DSUR) came into effect in late 2011, Chapter 2 (Pharmacovigilance Medical Writing for Clinical Trials) of the

More information

Standard Operating Procedures Guidelines for Good Clinical Practice

Standard Operating Procedures Guidelines for Good Clinical Practice SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA

More information

11.0 FDA-Regulated Research

11.0 FDA-Regulated Research 11.0 FDA-Regulated Research The HSC evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure

More information

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

1201 Maryland Avenue SW, Suite 900, Washington, DC , 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 28, 2010 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,

More information

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical

More information

SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES

SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES This policy applies to the following entity(s): Children s Hospital of Wisconsin Children s Hospital and Health System, Inc. Administrative Policy and Procedure Children s Research Institute SUBJECT: INSTITUTIONAL

More information

FDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives

FDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives Session Overview (1) Although the role of the Qualified Person responsible for Pharmacovigilance is mandated by the European legislation, the QPPV is held responsible for the establishment and the maintenance

More information

User Interface Considerations for Drug-Device Combination Products Submitted in an ANDA

User Interface Considerations for Drug-Device Combination Products Submitted in an ANDA User Interface Considerations for Drug-Device Combination Products Submitted in an ANDA Irene Z. Chan, PharmD, BCPS Deputy Director, Division of Medication Error Prevention and Analysis Disclaimer For

More information

What s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials

What s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials Vol. 14, No. 10, October 2018 Happy Trials to You What s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials While multiple, concurrently accruing patient cohorts in first-in-human (FIH)

More information

Drug Development - Points to Consider

Drug Development - Points to Consider Drug Development - Points to Consider The Regulator View ד"ר עפרה אקסלרוד מנהלת המכון לביקורת ותקנים של חומרי רפואה והאכיפה אוקטובר 2018 וס. מנהל מערך הרקוחות Keep in mind Know your product Know the regulatory

More information

Clinical aspects during Prequalification of vaccines. Olivier Lapujade World Health Organization, EMP/RHT/PQT

Clinical aspects during Prequalification of vaccines. Olivier Lapujade World Health Organization, EMP/RHT/PQT Clinical aspects during Prequalification of vaccines Olivier Lapujade World Health Organization, EMP/RHT/PQT lapujadeo@who.int 1 Chapter 8: Clinical experience Note 1 : Reference documents TRS 978, Annex

More information

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics 11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure

More information

Structure and content of an IMPD. What is required for first into man trial?

Structure and content of an IMPD. What is required for first into man trial? What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation

More information

Human Research Protection Program. Investigator Manual

Human Research Protection Program. Investigator Manual Human Research Protection Program Revised July 7, 2014 HRP-910 7/7/2014 2 of 10 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection

More information

Documentation requirements for an initial consultation

Documentation requirements for an initial consultation Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,

More information

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics 11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure

More information

Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry

Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

October, Integration and Implementation of CDISC Standards

October, Integration and Implementation of CDISC Standards Integration and Implementation of CDISC Standards October, 2008 Barbara Lentz, Associate Director, Electronic Data Management Standards, Processes & Training Pat Majcher, Statistical Reporting Services

More information

Structure and Mandate of FDA

Structure and Mandate of FDA Structure and Mandate of FDA Leonard Sacks, M.D. Office of Medical Policy Center for Drug Evaluation and Research FDA FDA Clinical Investigator Training Course November 13, 2018 Mission of regulatory agencies

More information